Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1997-02-03
1999-02-16
Wilson, James O.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
514 64, 424 181, 424 177, 424 9, A61K 3170
Patent
active
058721070
ABSTRACT:
Methods and compositions for treating urogenital tumors, and in particular, cancer of the prostate, bladder, and kidney, with BCNT, are disclosed. Any boron-containing compound that is sufficiently lipophilic to pass through the appropriate urogenital membranes in a quantity high enough to achieve therapy on irradiation with low-energy neutrons can be used. Carboranyl-containing nucleosides and oligonucleotides are particularly suited for use in BNCT of urogenital tumors. Preferred compounds include 5-carboranyl-2'-deoxyuridine (CDU) and 5-o-carboranyl-1-(2-deoxy-2-fluoro-.beta.-D-arabinofuranosyl)uracil (CFAU). Nucleosides and oligonucleotides bearing an (carboran-1-yl)phosphonate moiety can be used. Oligonucleotides of specific gene sequences that include one or more 3',5'-linking-(carboran-1-yl)phosphonate moieties can also be used in antisense therapy in the selective modification of gene expression. Compounds can be used in urogenital BNCT therapy that contain boron clusters as a means to enhance lipophilicity wherein the boron is not enriched in .sup.10 B, but instead, in the .sup.11 B isotope. The therapy is accomplished by administering the boron-containing compound by any appropriate route, including by intravenous injection, oral delivery or by catheter or other direct means, in such a manner that the compound accumulates in the target tumor. After desired accumulation of the compound in the tumor, the site is irradiated with an effective amount of low energy neutrons.
REFERENCES:
patent: 4516535 (1985-05-01), Russell, Jr. et al.
patent: 4855492 (1989-08-01), Spielvogel et al.
patent: 4959356 (1990-09-01), Miura et al.
patent: 5021572 (1991-06-01), Gabel
patent: 5066479 (1991-11-01), Hawthorne
patent: 5130302 (1992-07-01), Spielvogel et al.
patent: 5272250 (1993-12-01), Spielvogel et al.
patent: 5328678 (1994-07-01), Fujii et al.
patent: 5405598 (1995-04-01), Schinazi et al.
patent: 5466679 (1995-11-01), Soloway et al.
patent: 5599796 (1997-02-01), Schinazi et al.
Barth, et al., "Boron Neutron Capture Therapy of Cancer," Cancer Res., 50:1061-1070 (1990).
Barth, R. F.; Soloway, A. H.; Fairchild, R. G.; Brugger, R. M., "Boron Neutron Capture Therapy," Cancer, 70:2995-3008 (1992).
Cotton and Wilkinson, Advanced Inorganic Chemistry, Fourth Edition, John Wiley and Sons, 318-320 (1980).
Fairchild, R. G., et al., "In Vitro Determination of Uptake, Retention, Distribution, Biological Efficacy, and Toxicity and Boronated Compounds for Neuron Capture Therapy: A Comparison of Porphyrins with Sulfhydryl Boron Hydrides," Cancer Res., 50:4860-4865 (1990).
Fairchild, R.G., Gabel, D., Laster B., and Kiszenick, W. "Boron-10 Analysis by Prompt-gamma and Track Etching Techniques", the First National Symposium on Neutron Capture Therapy, Oct. 12-14, 1983.
Fulcrand-El Kattan, et al., "Carboranyl Oligonucleotides, 2, Synthesis and Physiochemical Properties of Dodecathymidylate Containing 5-(o-Carboran-1-yl)-2'-deoxyuridine," J. Am. Chem. Soc., 116(17):7494-7501 (1994).
Gabel, D., Hocke, I., and Elsen, W., "Determination of sub-ppm amounts of boron-10 solutions by means of solid state track detectors," Phys. Med. Biol., 28:1453-1457 (1983).
Goudgaon, N.M., El-Kattan, G.F., and Schinazi, R.F., "Boron containing pyrimidines, nucelosides, and oligonucleotides for neutron capture therapy," Nucleosides & Nucleotides, 13:849-880 (1994).
Hatanaka and Sano, "A Revised Boron-Neutron Capture Therapy for Malignant Brain Tumor," Z. Neurol., 204:309-332 (1973).
Hawthorne, "The Role of Chemistry in the Development of Boron Neutron Capture Therapy of Cancer Therapy of Cancer," Angew. Chem. Int. Ed. Engl. 32:950-984 (1983).
Heying, T. L. et al., "A new series of organoboranes, (I) Carboranes from the reaction of decaborane with acetylenic compounds," Inorg. Chem. 1963, 2, 1089-1092.
Keane, T.E., et al., "Combination versus single agent therapy in effecting complete therapeutic response in human bladder cancer: analysis of cisplatin and/or 5-fluorouracil in an vivo survival model" Cancer Res., 54:475-481 (1994).
Keane, T.E., Rosner, G., Gingrich, J., Poulton, S., and Walther, P., "The therapeutic impact of dipyridamole: chemopotentiation of the cytotoxic combination 5-fluorouracil/cisplatin in an animal model of human bladder cancer," J. Urol., 146:1418-1424 (1991).
Keane, T.E., Rosner, G., Donaldson, J., Norwood, D., Poulton, S.H., and Walther, P.J., "Dipyridamole-cisplatin potentiation in xenograft models of human testicular and bladder testicular and bladder cancer," J. Urol., 144:1004-1009 (1990).
Lesnikowski, Z. J., "Stereocontrolled Synthesis of P-Chiral Analogues of Oligonucleotides," Bioorganic Chem., 21:127-155. (1993).
Marshall and Caruthers, "Phosphorodithioate DNA as a Potential Therapeutic Drug," Science 259:1564-1570 (1993).
Milligan, J.F., Matteucci, M.D., Martin, J.C., "Current Concepts in Antisense Drug Design," J. Med. Chem., 36(14):1923-1937 (1993).
Reynolds, R. C.; Trask, T. W.; Sedwick, W. D., "2,4-Dichloro-5-(carboranlymethyl)-6-methylpyrimidine: A Potential Synthon for 5-(1-o-Carboranylmethyl)pyrimidines," J. Org. Chem. 56:2391-2395 (1991).
Schinzai, R. F., Prusoff, W. H., "Synthesis and Properties of Boron and Silicon Substituted Uracil or 2'-Deoxyuridine," Tetrahedron Lett 50:4981-4984 (1978).
Schinazi, R. F., et al., "Synthesis, Antiviral Activity, Cytotoxicity, and Cellular Pharmacology of 5-Carboranyl-Pyrimidine Nucleosides," Advances in Neutron Capture Therapy, Plenum Press: New York and London, pp. 285-288 (1993).
Schinazi, R. F., et al., "Synthesis, Biological Activity, and Cellular Pharmacology of 5-Carborany-Pyrimidine Nucleosides," Tenth International Roundtable: Nucleotides and Nucleosides, Park City, Utah; p.28 (1993).
Schinazi, R.F.; Prusoff, W. H., "Synthesis of 5-(Dihydrozboryl)-2'-deoxyuridine and Related Boron-Containing Pyrimidines," J. Org. Chem., 50:841-847 (1985).
Sood, A., Spielyogel, B. F.; Shaw, B. R. J., "Boron-Containing Nucleic Acids: Synthesis of Cyanoborane Adducts of 2'-Deoxynucleosides," Am. Chem. Soc. 111:9234-9235 (1989).
Sood, A.: Shaw, B. R.; Spielvogel, B. F., "Boron-Containing Nucleic Acids. 2. 1 Synthesis of Oligodeoxynucleoside Boranophosphates," J. Am. Chem. Soc. 112:9000-9001 (1990).
Su, et al., "Nucleosides, 136, Synthesis and Antiviral Effects of Several 1-(Deoxy-20fluoro-B-D-arabinofuranosyl)-5-alkyluracils. Some Structure-Activity Relationships," J. Med. Chem., 29:151-154 (1986).
Tolpin, et al., "Boron Neutron Capture Therapy of Cerebral Gliomas," Onocology, 32:223-246 (1975).
Uhlmann and Peyman, "Antisense Oligonucleotides: A New Therapeutic Principle" Chemical Reviews, 90(4):544-584 (Jun. 1990).
Van Roey, P., et al., "Absolute configuration of the antiviral agent Antiviral Chem. Chemotherapy, 4:369-375 (1993).
Vorbruggen, H. and Hofle, G., "On the mechanism of nucleoside synthesis," Chem. Ber. 114:1256-1268 (1981).
Wilson and Liotta, "A general method for controlling glycosylation stereochemistry in the synthesis of 2'-deoxyribose nucleosides," Tetrahedron Lett., 31:1815-1818 (1990).
Wilson, J.G., "Synthesis Approaches to a Carboranyl Thiouracil," Pigment Cell Res., 2:297-303 (1989).
Yamamoto, et al., "Synthesis of Carboranes Containing Nucleoside Bases. Unexpectedly High Cytostatic and Cytocidal Toxicity towards Cancer Cells," J.Chem. Soc., Chem. Commun., 157-158 (1992).
Yamamoto, Y.; Seko, T.; Nakamura, H., "Synthesis of Carboranes Containing Nucleoside Bases." Heteroatom. Chem., 3:239-244 (1992).
Zamenhof, R. G.; Kalend, A. M.; and Bloomer, W. D., "BNCT: Looking for a Few Good Molecules," J. Nat'l Cancer Inst., 84:1290-1291 (1992).
"N.Y. cancer patient fights for novel radiation therapy," The Atlanta Journal/Contstitute, Sep. 17, 1994.
Chemical Abstracts 114:224582, 1991.
Charng-Jui Chen, et al., "Synthesis and Characterization of Oligomeric nido-Carboranyl Phosphate Diester Conjugates to Antibody and Antibody Fragments for Potential Use in Boron Neurton Capture Therapy of Solid Tumors," Bioconjugate Chemistry, vol. 5, No. 6, Nov. 1, 1994, pp. 557-564.
Orn-Anong Pettersson, et al., "Accumulation of 10B in the Central Degenerative Ar
Keane Thomas E.
Liotta Dennis C.
Schinazi Raymond F.
Emory University
Haley Jacqueline
Knowles Sherry M.
Wilson James O.
LandOfFree
Treatment of urogenital cancer with boron neutron capture therap does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of urogenital cancer with boron neutron capture therap, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of urogenital cancer with boron neutron capture therap will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2062636